NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 614
- Registration Number
- NCT00664742
- Locations
- 🇹🇷
Götzepe Education and Research Hospital, Istanbul, Turkey
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 6
- Registration Number
- NCT00663169
- Locations
- 🇬🇧
Novartis Investigator Site, Glasgow, United Kingdom
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 920
- Registration Number
- NCT00662649
- Locations
- 🇹🇷
Novartis Investigational Site, Yenisehir/Izmir, Turkey
🇮🇱Novaratis Investigative Site, Ashkelon, Israel
🇬🇧Novartis Investigative Site, Sheffield, United Kingdom
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 122
- Registration Number
- NCT00658320
- Locations
- 🇯🇵
Novartis Pharma K.K., Japan, Tokyo, Japan
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 328
- Registration Number
- NCT00654875
- Locations
- 🇪🇸
Investigative Site, Valencia, Spain
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00651105
- Locations
- 🇩🇪
Novartis Investigator Site, Berlin, Germany
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 360
- Registration Number
- NCT00649883
- Locations
- 🇬🇹
Dr. Carlos Fernando Grazioso Aragón, Guatemala City, Guatemala
🇬🇹Centro Clínico La Quinta, Guatemala City, Guatemala
🇬🇹Clínicas Dr. Rafael Montiel, Guatemala City, Guatemala
Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00646503
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00646737
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, Brazil
© Copyright 2024. All Rights Reserved by MedPath